The stock of Immunic Inc (IMUX) has gone down by -11.21% for the week, with a -12.84% drop in the past month and a -40.25% drop in the past quarter. The volatility ratio for the week is 7.41%, and the volatility levels for the past 30 days are 6.64% for IMUX. The simple moving average for the last 20 days is -8.30% for IMUX stock, with a simple moving average of -26.54% for the last 200 days.
Is It Worth Investing in Immunic Inc (NASDAQ: IMUX) Right Now?
The 36-month beta value for IMUX is also noteworthy at 1.87. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for IMUX is 87.36M, and at present, short sellers hold a 6.46% of that float. The average trading volume of IMUX on January 22, 2025 was 1.05M shares.
IMUX) stock’s latest price update
The stock of Immunic Inc (NASDAQ: IMUX) has decreased by -0.31 when compared to last closing price of 0.95. Despite this, the company has experienced a -11.21% fall in its stock price over the last five trading sessions. proactiveinvestors.com reported 2025-01-11 that Immunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio joined Proactive to discuss the company’s progress in advancing its novel therapy vidofludimus calcium. He discussed the significant milestones achieved in 2024, such as the positive interim analysis of the ENSURE trials in relapsing multiple sclerosis (MS) and the anticipation of the results from the CALLIPER progressive MS study in April 2025.
Analysts’ Opinion of IMUX
Many brokerage firms have already submitted their reports for IMUX stocks, with H.C. Wainwright repeating the rating for IMUX by listing it as a “Buy.” The predicted price for IMUX in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on November 25, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see IMUX reach a price target of $5. The rating they have provided for IMUX stocks is “Outperform” according to the report published on September 09th, 2024.
B. Riley Securities gave a rating of “Buy” to IMUX, setting the target price at $6 in the report published on August 27th of the previous year.
IMUX Trading at -14.87% from the 50-Day Moving Average
After a stumble in the market that brought IMUX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.98% of loss for the given period.
Volatility was left at 6.64%, however, over the last 30 days, the volatility rate increased by 7.41%, as shares sank -7.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.17% lower at present.
During the last 5 trading sessions, IMUX fell by -11.21%, which changed the moving average for the period of 200-days by -22.13% in comparison to the 20-day moving average, which settled at $1.0360. In addition, Immunic Inc saw -5.00% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMUX starting from Rudick Richard Alan, who purchase 87,300 shares at the price of $1.15 back on Nov 12 ’24. After this action, Rudick Richard Alan now owns 87,300 shares of Immunic Inc, valued at $100,369 using the latest closing price.
Stock Fundamentals for IMUX
The total capital return value is set at -2.31. Equity return is now at value -216.24, with -147.12 for asset returns.
Based on Immunic Inc (IMUX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -84.35. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -47.64.
Currently, EBITDA for the company is -99.11 million with net debt to EBITDA at 0.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.71.
Conclusion
In summary, Immunic Inc (IMUX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
